Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) dropped 2.2% during trading on Friday . The company traded as low as $6.55 and last traded at $6.8450. Approximately 5,071 shares traded hands during trading, an increase of 39% from the average daily volume of 3,661 shares. The stock had previously closed at $7.00.
Telix Pharmaceuticals Price Performance
The business has a 50-day simple moving average of $7.97 and a two-hundred day simple moving average of $9.63.
About Telix Pharmaceuticals
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- NEW LAW: Congress Approves Setup For Digital Dollar?
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- What a Former CIA Agent Knows About the Coming Collapse
- Trade this between 9:30 and 10:45 am EST
- When to buy gold (mathematically)
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
